
Soleno Therapeutics (SLNO) Stock Forecast & Price Target
Soleno Therapeutics (SLNO) Analyst Ratings
Bulls say
Soleno Therapeutics has demonstrated strong financial performance, with a preliminary unaudited net revenue for full-year 2025 projected between $90 million and $92 million, significantly surpassing previous forecasts. The company's product VYKAT XR is expected to generate up to $2.3 billion in peak annual sales in the U.S., with initial sales figures since its launch in 2Q25 already ranging from $189 million to $191 million. Additionally, Soleno maintains a robust financial position with an anticipated cash balance of approximately $500 million by the end of 2025, providing the company with ample resources for future growth initiatives, including potential mergers and acquisitions.
Bears say
Soleno Therapeutics Inc. faces a negative outlook primarily due to several financial and operational risks, including market access and reimbursement issues that may hinder the uptake of its product candidate, DCCR. The company is also anticipating earlier-than-expected generic erosion of the DCCR franchise, which could diminish potential revenue streams. Additionally, Soleno's inability to effectively optimize DCCR's value outside the U.S. further contributes to concerns about its long-term profitability and market position.
This aggregate rating is based on analysts' research of Soleno Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Soleno Therapeutics (SLNO) Analyst Forecast & Price Prediction
Start investing in Soleno Therapeutics (SLNO)
Order type
Buy in
Order amount
Est. shares
0 shares